Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration

Mehat MS., Sundaram V., Ripamonti C., Robson AG., Smith AJ., Borooah S.

Clinical Trial with a reported sample of 4 on Chronic Inflammation, published in Ophthalmology (2018) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Ophthalmology (2018)
Reported sample size
4
Source database
Europe PMC
PMID
29884405
PMCID
PMC6195794
DOI
10.1016/j.ophtha.2018.04.037
NCT
NCT01469832
Citations
208

Abstract (original English)

Purpose Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area. Design Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832). Participants Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults. Methods Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks. Main outcome measures The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT. Results Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improveme

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMacular DegenerationImmunosuppressive AgentsTomography, Optical CoherenceFluorescein AngiographyElectroretinographySickness Impact ProfileVisual AcuityVisual FieldsQuality of Life

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research